id	sid	eid	entity	type
ajlm-880	1	1	university of zimbabwe college of health science	ORG
ajlm-880	1	2	harare	GPE
ajlm-880	1	3	zimbabwe	GPE
ajlm-880	1	4	andrew j. ocque center	PERSON
ajlm-880	1	5	new york	GPE
ajlm-880	1	6	university of new york	ORG
ajlm-880	1	7	buffalo	GPE
ajlm-880	1	8	new york	GPE
ajlm-880	1	9	united states	GPE
ajlm-880	1	10	robin difrancesco	PERSON
ajlm-880	1	11	new york	GPE
ajlm-880	1	12	university of new york	ORG
ajlm-880	1	13	buffalo	GPE
ajlm-880	1	14	new york	GPE
ajlm-880	1	15	united states	GPE
ajlm-880	1	16	charles maponga	PERSON
ajlm-880	1	17	university of zimbabwe college of health science	ORG
ajlm-880	1	18	harare	GPE
ajlm-880	1	19	zimbabwe	GPE
ajlm-880	1	20	new york	GPE
ajlm-880	1	21	university of new york	ORG
ajlm-880	1	22	buffalo	GPE
ajlm-880	1	23	new york	GPE
ajlm-880	1	24	united states	ORG
ajlm-880	1	25	farai muzambi international pharmacology specialty laboratory	ORG
ajlm-880	1	26	university of zimbabwe college of health science	ORG
ajlm-880	1	27	harare	GPE
ajlm-880	1	28	zimbabwe	GPE
ajlm-880	1	29	g. monera-penduka international	PERSON
ajlm-880	1	30	university of zimbabwe college of health science	ORG
ajlm-880	1	31	harare	GPE
ajlm-880	1	32	zimbabwe	GPE
ajlm-880	1	33	university of zimbabwe college of health science	ORG
ajlm-880	1	34	harare	GPE
ajlm-880	1	35	zimbabwe	GPE
ajlm-880	1	36	j. mtisi international pharmacology specialty laboratory	ORG
ajlm-880	1	37	university of zimbabwe college of health science	ORG
ajlm-880	1	38	harare	GPE
ajlm-880	1	39	zimbabwe	GPE
ajlm-880	1	40	d. morse	ORG
ajlm-880	1	41	new york	GPE
ajlm-880	1	42	university of new york	ORG
ajlm-880	1	43	buffalo	GPE
ajlm-880	1	44	new york	GPE
ajlm-880	1	45	united states	ORG
ajlm-880	1	46	ocque aj	PERSON
ajlm-880	1	47	difrancesco r	PERSON
ajlm-880	2	1	afr j	PERSON
ajlm-880	2	2	2019;8(1	CARDINAL
ajlm-880	2	3	a880	PERSON
ajlm-880	2	4	andrew j. ocque	PERSON
ajlm-880	2	5	robin difrancesco	PERSON
ajlm-880	2	6	charles maponga	PERSON
ajlm-880	2	7	farai muzambi	ORG
ajlm-880	2	8	g. monera-penduka	PERSON
ajlm-880	2	9	j. mtisi	PERSON
ajlm-880	2	10	gene d. morse	PERSON
ajlm-880	2	11	26	CARDINAL
ajlm-880	2	12	july 2018	DATE
ajlm-880	2	13	02 nov. 2018	DATE
ajlm-880	2	14	16 may 2019	CARDINAL
ajlm-880	2	15	2019	DATE
ajlm-880	6	1	nevirapine pharmacokinetics	ORG
ajlm-880	8	1	2795	CARDINAL
ajlm-880	8	2	2996	CARDINAL
ajlm-880	8	3	atlantis	PRODUCT
ajlm-880	8	4	dc18 5 micron	PRODUCT
ajlm-880	8	5	3.9 mm	QUANTITY
ajlm-880	8	6	150 mm	QUANTITY
ajlm-880	8	7	1 ml/min	QUANTITY
ajlm-880	8	8	210	CARDINAL
ajlm-880	8	9	400	CARDINAL
ajlm-880	8	10	260	CARDINAL
ajlm-880	9	1	0.995	CARDINAL
ajlm-880	9	2	12.0%	PERCENT
ajlm-880	10	1	between 98.8% and 114%	PERCENT
ajlm-880	11	1	african	NORP
ajlm-880	14	1	first	ORDINAL
ajlm-880	14	2	zimbabwe	GPE
ajlm-880	15	1	nevirapine	ORG
ajlm-880	16	1	several united states	GPE
ajlm-880	16	2	national institutes of health programmes	ORG
ajlm-880	20	1	african	NORP
ajlm-880	20	2	analyte.4	ORG
ajlm-880	33	1	national agencies accepting drug	ORG
ajlm-880	34	1	harare	GPE
ajlm-880	34	2	zimbabwe	GPE
ajlm-880	35	1	2013	DATE
ajlm-880	35	2	harare	GPE
ajlm-880	35	3	zimbabwe	GPE
ajlm-880	35	4	130/10	DATE
ajlm-880	35	5	harare	GPE
ajlm-880	35	6	zimbabwe	GPE
ajlm-880	35	7	zimbabwe	GPE
ajlm-880	35	8	harare	GPE
ajlm-880	35	9	zimbabwe	GPE
ajlm-880	36	1	atazanavir	PERSON
ajlm-880	36	2	ritonavir, lopinavir	ORG
ajlm-880	36	3	lamivudine	ORG
ajlm-880	36	4	stavudine	GPE
ajlm-880	37	1	nevirapine powder	ORG
ajlm-880	37	2	90%	PERCENT
ajlm-880	37	3	89%	PERCENT
ajlm-880	38	1	harare	GPE
ajlm-880	38	2	zimbabwe	GPE
ajlm-880	39	1	hplc-grade methanol	ORG
ajlm-880	39	2	microsep	ORG
ajlm-880	39	3	romil pure chemistry	ORG
ajlm-880	39	4	johannesburg	GPE
ajlm-880	39	5	south africa	GPE
ajlm-880	40	1	harare	GPE
ajlm-880	40	2	zimbabwe	GPE
ajlm-880	41	1	2795	CARDINAL
ajlm-880	41	2	milford	GPE
ajlm-880	41	3	massachusetts	GPE
ajlm-880	41	4	united states	GPE
ajlm-880	41	5	2998	CARDINAL
ajlm-880	41	6	3	CARDINAL
ajlm-880	41	7	waters associates	ORG
ajlm-880	41	8	milford	GPE
ajlm-880	41	9	massachusetts	GPE
ajlm-880	41	10	united states	GPE
ajlm-880	42	1	atlantis	PRODUCT
ajlm-880	42	2	dc18 3.9 mm ×	PRODUCT
ajlm-880	42	3	20 mm	QUANTITY
ajlm-880	42	4	5	DATE
ajlm-880	43	1	1	CARDINAL
ajlm-880	43	2	10 mm	QUANTITY
ajlm-880	43	3	2	CARDINAL
ajlm-880	43	4	10 mm	QUANTITY
ajlm-880	43	5	20:50:30	TIME
ajlm-880	43	6	0–3 min	QUANTITY
ajlm-880	43	7	100%	PERCENT
ajlm-880	43	8	4 min – 7 min	TIME
ajlm-880	43	9	100%	PERCENT
ajlm-880	43	10	7.01 min	QUANTITY
ajlm-880	43	11	10 min	QUANTITY
ajlm-880	43	12	100%	PERCENT
ajlm-880	44	1	1 ml	QUANTITY
ajlm-880	45	1	40 °	QUANTITY
ajlm-880	46	1	65	CARDINAL
ajlm-880	47	1	210	CARDINAL
ajlm-880	47	2	400	CARDINAL
ajlm-880	47	3	260	CARDINAL
ajlm-880	47	4	3	CARDINAL
ajlm-880	48	1	the united states food	GPE
ajlm-880	48	2	five mg	QUANTITY
ajlm-880	49	1	100%	PERCENT
ajlm-880	51	1	100	CARDINAL
ajlm-880	51	2	250	CARDINAL
ajlm-880	52	1	10 min at 7852	TIME
ajlm-880	52	2	vwr labconco	ORG
ajlm-880	52	3	kansas city	GPE
ajlm-880	52	4	missouri	GPE
ajlm-880	52	5	united states	GPE
ajlm-880	52	6	50 °	QUANTITY
ajlm-880	53	1	200	CARDINAL
ajlm-880	56	1	500 ng/ml	QUANTITY
ajlm-880	56	2	1000 ng/ml	QUANTITY
ajlm-880	56	3	5000 ng/ml	QUANTITY
ajlm-880	56	4	10 000 ng/ml	QUANTITY
ajlm-880	57	1	500 ng	QUANTITY
ajlm-880	57	2	greater than 20%	PERCENT
ajlm-880	58	1	loq	ORG
ajlm-880	58	2	fda	ORG
ajlm-880	59	1	loq	ORG
ajlm-880	59	2	six	CARDINAL
ajlm-880	59	3	65	CARDINAL
ajlm-880	61	1	15 000 ng/ml	QUANTITY
ajlm-880	61	2	13 000 ng/ml	QUANTITY
ajlm-880	61	3	8000 ng/ml	QUANTITY
ajlm-880	61	4	4000 ng/ml	QUANTITY
ajlm-880	61	5	1000 ng/ml	QUANTITY
ajlm-880	61	6	500 ng	QUANTITY
ajlm-880	61	7	lloq	PERSON
ajlm-880	61	8	500 ng/ml	QUANTITY
ajlm-880	61	9	1500 ng/ml	QUANTITY
ajlm-880	61	10	5000 ng/ml	QUANTITY
ajlm-880	61	11	12 000 ng/ml	QUANTITY
ajlm-880	62	1	1/x2	CARDINAL
ajlm-880	63	1	six	CARDINAL
ajlm-880	63	2	qc	LOC
ajlm-880	63	3	3 days	DATE
ajlm-880	63	4	each day	DATE
ajlm-880	64	1	45 000 ng/ml	QUANTITY
ajlm-880	64	2	two	CARDINAL
ajlm-880	64	3	1:4	CARDINAL
ajlm-880	66	1	6	CARDINAL
ajlm-880	67	1	4 °	QUANTITY
ajlm-880	67	2	168	CARDINAL
ajlm-880	67	3	six	CARDINAL
ajlm-880	68	1	abacavir	PERSON
ajlm-880	68	2	lamivudine	PERSON
ajlm-880	68	3	atazanavir	GPE
ajlm-880	68	4	ritonavir	PERSON
ajlm-880	69	1	twenty	CARDINAL
ajlm-880	69	2	10 µg/ml	QUANTITY
ajlm-880	69	3	50 µg	QUANTITY
ajlm-880	69	4	180	CARDINAL
ajlm-880	70	1	one	CARDINAL
ajlm-880	70	2	one gram	QUANTITY
ajlm-880	71	1	15 min, 20	TIME
ajlm-880	71	2	180	CARDINAL
ajlm-880	73	1	six	CARDINAL
ajlm-880	75	1	the united states	GPE
ajlm-880	75	2	national institute of allergies	ORG
ajlm-880	75	3	±20%	PERCENT
ajlm-880	75	4	four	CARDINAL
ajlm-880	75	5	200 mg	QUANTITY
ajlm-880	75	6	daily	DATE
ajlm-880	76	1	1.85	CARDINAL
ajlm-880	78	1	400	CARDINAL
ajlm-880	78	2	180	CARDINAL
ajlm-880	79	1	550	CARDINAL
ajlm-880	79	2	85%	PERCENT
ajlm-880	82	1	4.5 min	QUANTITY
ajlm-880	82	2	5.9 min	QUANTITY
ajlm-880	82	3	10 min	TIME
ajlm-880	82	4	1	CARDINAL
ajlm-880	83	1	5.39%	PERCENT
ajlm-880	84	1	1	CARDINAL
ajlm-880	85	1	500 ng/ml	QUANTITY
ajlm-880	85	2	15 000 ng/ml	QUANTITY
ajlm-880	86	1	2	CARDINAL
ajlm-880	86	2	±15%	PERCENT
ajlm-880	88	1	+8.83%	PERCENT
ajlm-880	88	2	12%	PERCENT
ajlm-880	89	1	qc	LOC
ajlm-880	89	2	united states food and drug administration	ORG
ajlm-880	89	3	1	CARDINAL
ajlm-880	90	1	9.69%	PERCENT
ajlm-880	90	2	+12.0%	PERCENT
ajlm-880	90	3	mqc	ORG
ajlm-880	91	1	lloq	PERSON
ajlm-880	91	2	7.53%	PERCENT
ajlm-880	91	3	+16.1%	PERCENT
ajlm-880	92	1	2.84%	PERCENT
ajlm-880	92	2	+4.96%	PERCENT
ajlm-880	92	3	1:4	CARDINAL
ajlm-880	92	4	1:8	CARDINAL
ajlm-880	93	1	1	CARDINAL
ajlm-880	93	2	university of zimbabwe international pharmacology laboratory	ORG
ajlm-880	93	3	2016	DATE
ajlm-880	94	1	2	CARDINAL
ajlm-880	94	2	nevirapine calibration	PERSON
ajlm-880	95	1	2	CARDINAL
ajlm-880	96	1	3	CARDINAL
ajlm-880	96	2	4	DATE
ajlm-880	96	3	nevirapine	GPE
ajlm-880	97	1	103% to 114%	PERCENT
ajlm-880	97	2	98.8%	PERCENT
ajlm-880	98	1	2	CARDINAL
ajlm-880	98	2	university of zimbabwe international pharmacology laboratory	ORG
ajlm-880	99	1	3	CARDINAL
ajlm-880	99	2	chromatogram	PERSON
ajlm-880	100	1	4	CARDINAL
ajlm-880	100	2	chromatogram	PERSON
ajlm-880	101	1	5	CARDINAL
ajlm-880	101	2	chromatogram	PERSON
ajlm-880	102	1	20%	PERCENT
ajlm-880	103	1	20%	PERCENT
ajlm-880	103	2	-13%	PERCENT
ajlm-880	103	3	chromatogram	PERSON
ajlm-880	103	4	6	CARDINAL
ajlm-880	104	1	6	CARDINAL
ajlm-880	104	2	chromatogram	PERSON
ajlm-880	105	1	2013	DATE
ajlm-880	105	2	university of zimbabwe international pharmacology laboratory	ORG
ajlm-880	107	1	chromatogram	PERSON
ajlm-880	108	1	180	CARDINAL
ajlm-880	108	2	nevirapine assay	ORG
ajlm-880	108	3	500	CARDINAL
ajlm-880	108	4	patients4	PERSON
ajlm-880	109	1	manifolds	ORG
ajlm-880	113	1	nevirapine assay	ORG
ajlm-880	118	1	united states	GPE
ajlm-880	118	2	buffalo	GPE
ajlm-880	118	3	new york	GPE
ajlm-880	118	4	united states	GPE
ajlm-880	119	1	alfred tarumbwa	PERSON
ajlm-880	119	2	lorellie mungure	PERSON
ajlm-880	121	1	the university of zimbabwe international pharmacology specialty laboratory	ORG
ajlm-880	121	2	the united states	GPE
ajlm-880	121	3	national institute of allergy	ORG
ajlm-880	121	4	um1 ai106701	PERSON
ajlm-880	122	1	university of zimbabwe hiv	ORG
ajlm-880	122	2	the fogarty international center under	ORG
ajlm-880	122	3	tw010313	PERSON
ajlm-880	123	1	the fogarty international center	ORG
ajlm-880	129	1	c.m.	PERSON
ajlm-880	136	1	geneva	GPE
ajlm-880	136	2	2016	DATE
ajlm-880	136	3	2016	CARDINAL
ajlm-880	136	4	2018	DATE
ajlm-880	136	5	sept 19	DATE
ajlm-880	137	1	mtisi tj	PERSON
ajlm-880	137	2	maponga	GPE
ajlm-880	137	3	monera-penduka tg	ORG
ajlm-880	139	1	afr j	PERSON
ajlm-880	140	1	2018;7(1):659	CARDINAL
ajlm-880	140	2	t	GPE
ajlm-880	140	3	maponga cc	GPE
ajlm-880	141	1	zimbabwe	GPE
ajlm-880	143	1	niessens wma	PERSON
ajlm-880	143	2	correa cr	PERSON
ajlm-880	146	1	nj	ORG
ajlm-880	146	2	john wiley	PERSON
ajlm-880	146	3	2017	DATE
ajlm-880	147	1	2018	DATE
ajlm-880	147	2	15	CARDINAL
ajlm-880	148	1	vajpayee m	PERSON
ajlm-880	148	2	mohan t.	PERSON
ajlm-880	149	1	indian	NORP
ajlm-880	150	1	2011;134(6):801–822	CARDINAL
ajlm-880	151	1	alamri rg	PERSON
ajlm-880	151	2	mohsin k	PERSON
ajlm-880	151	3	ahmad	PERSON
ajlm-880	151	4	alanazi	PERSON
ajlm-880	152	1	saudi	NORP
ajlm-880	152	2	j. 2017;25(1):128–135	ORG
ajlm-880	152	3	sarkar m	PERSON
ajlm-880	152	4	khandavilli s	PERSON
ajlm-880	152	5	panchagnula r. development	PERSON
ajlm-880	155	1	alothman za	PERSON
ajlm-880	155	2	rahman n.	PERSON
ajlm-880	156	1	arab	NORP
ajlm-880	157	1	2017;10	CARDINAL
ajlm-880	158	1	https://doi.org/10.1016/j.arabjc.2013.04.016 holland	PERSON
ajlm-880	158	2	difrancesco r	PERSON
ajlm-880	159	1	antimicrob	PERSON
ajlm-880	160	1	2004;48(3):824–831	CARDINAL
ajlm-880	160	2	al-hassan aa	PERSON
ajlm-880	161	1	saudi	NORP
ajlm-880	161	2	2015;23(6):689–697	CARDINAL
ajlm-880	162	1	https://doi.org/10.1016/j.jsps.2015.01.023 duarte da costa cunha br	ORG
ajlm-880	162	2	passos da cunha c	PERSON
ajlm-880	162	3	tandem	ORG
ajlm-880	163	1	braz	ORG
ajlm-880	163	2	biol technol	PERSON
ajlm-880	164	1	2013;56:911–920	CARDINAL
ajlm-880	165	1	kopec	GPE
ajlm-880	165	2	schweiggert rm	PERSON
ajlm-880	165	3	riedl km	PERSON
ajlm-880	165	4	carle	ORG
ajlm-880	165	5	schwartz	PERSON
ajlm-880	167	1	https://doi.org/10.1002/rcm.6576 stanczyk fz	PERSON
ajlm-880	167	2	clarke nj	PERSON
ajlm-880	169	1	riska p	PERSON
ajlm-880	169	2	lamson m	ORG
ajlm-880	169	3	macgregor t	PERSON
ajlm-880	170	1	j soc pharm	PERSON
ajlm-880	170	2	1999	DATE
ajlm-880	171	1	2018	DATE
ajlm-880	171	2	oct 2];27(8):891–895	DATE
ajlm-880	176	1	rockville	GPE
ajlm-880	176	2	md	GPE
ajlm-880	176	3	fda	ORG
ajlm-880	176	4	2001	DATE
ajlm-880	176	5	2001 feb 22	DATE
ajlm-880	176	6	2018	DATE
ajlm-880	178	1	nevirapine	FAC
ajlm-880	178	2	lamivudine	ORG
ajlm-880	178	3	malawian	NORP
ajlm-880	178	4	30	CARDINAL
ajlm-880	181	1	https://doi.org/10.3851/imp1544	CARDINAL
ajlm-880	181	2	wang j	PERSON
ajlm-880	182	1	chinese	NORP
ajlm-880	183	1	plos	PERSON
ajlm-880	183	2	one	CARDINAL
ajlm-880	184	1	2011;6(10):e26739	CARDINAL
ajlm-880	185	1	gopalan bp	ORG
ajlm-880	185	2	mehta k	PERSON
ajlm-880	187	1	plos one	PERSON
ajlm-880	188	1	2017;12(8):e0183080	CARDINAL
ajlm-880	189	1	rosenkranz sl	PERSON
ajlm-880	189	2	taylor cr	PERSON
ajlm-880	192	1	2013;35(5):631	CARDINAL
ajlm-880	193	1	monera-penduka tg	ORG
ajlm-880	193	2	maponga cc	GPE
ajlm-880	193	3	wolfe ar	PERSON
ajlm-880	193	4	wiesner l	ORG
ajlm-880	193	5	nhachi cfb	ORG
ajlm-880	195	1	one	CARDINAL
ajlm-880	197	1	2017;14(1):12	CARDINAL
ajlm-880	197	2	halde s	GPE
ajlm-880	197	3	chintamaneni m	ORG
ajlm-880	197	4	indian	NORP
ajlm-880	197	5	sci	ORG
ajlm-880	198	1	2011;73(4):416–421	CARDINAL
ajlm-880	198	2	venkata kumar h.	PERSON
ajlm-880	198	3	ananth kumar	PERSON
ajlm-880	201	1	issn	PERSON
ajlm-880	201	2	0973-4945	CARDINAL
ajlm-880	201	3	2018	DATE
ajlm-880	204	1	2002;774(2):127–140	CARDINAL
ajlm-880	205	1	tidwell rr	PERSON
ajlm-880	206	1	delavirdine	GPE
ajlm-880	209	1	jangid ag	PERSON
ajlm-880	209	2	sanyal m	ORG
ajlm-880	209	3	shrivastav	DATE
ajlm-880	209	4	stavudine	GPE
ajlm-880	211	1	https://doi.org/10.1016/j.jchromb.2007.03.047 mustafa s	PERSON
ajlm-880	211	2	hassan nb.	PERSON
ajlm-880	211	3	2-oh	QUANTITY
ajlm-880	211	4	3-oh	QUANTITY
ajlm-880	212	1	j pharma tech	PERSON
ajlm-880	213	1	2014;6(1):49–52	CARDINAL
ajlm-880	214	1	cpqa	PERSON
ajlm-880	216	1	university of new york	ORG
ajlm-880	216	2	buffalo	GPE
ajlm-880	216	3	2016	DATE
ajlm-880	217	1	charbe n	PERSON
ajlm-880	217	2	baldelli s	PERSON
ajlm-880	217	3	castoldi s	PERSON
ajlm-880	217	4	clementi e. development	PERSON
ajlm-880	217	5	nine	CARDINAL
ajlm-880	219	1	stewart jt	PERSON
ajlm-880	222	1	2002;28(5):903–908	CARDINAL